LY 333006
Latest Information Update: 03 Feb 2000
Price :
$50 *
At a glance
- Originator Eli Lilly and Company
- Class Anti-infectives
- Mechanism of Action Glucan synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 03 Feb 2000 No-Development-Reported for Mycoses in USA (IV)
- 01 May 1997 New profile
- 01 May 1997 Preclinical development for Mycoses in USA (IV)